Territorial Availability: Available through Bertin Technologies only in France
- Product Overview:
Cayman’s Protease Activity Assay Kit provides a convenient method for determining the activity of proteases in samples. Proteolytic digestion of the FITC-casein substrate can be monitored by changes in either fluorescence polarization (FP) or total fluorescence.{33943} Fluorescence is the ability of a molecule to absorb the energy of an incoming (excitation) photon and then re-emit this energy as a new, slightly less energetic (emission) photon. A small fluorescent molecule will rotate appreciably during the very small interval of time between absorption of a photon and emission of the fluorescence photon. If the excitation light is polarized, this rotation will result in randomization of the plane of the emitted light. Thus, small fluorescent molecules depolarize an excitation pulse of polarized light. Large fluorescent molecules, like FITC-casein, do not rotate as appreciably in the same small interval of time. They will, therefore, emit light that retains some of the polarization of the polarized excitation light. This polarization is quantified as millipolarization units, or mP. In this assay, the total FP decreases as the FITC-casein is digested into smaller, quicker rotating fluorescein-labeled fragments. If measuring FP is not available, the change in total fluorescence can also be measured to determine protease activity. The conjugation of FITC to casein results in moderate quenching of the total fluorescence. This fluorescence increases as the FITC-casein substrate is digested into smaller fluorescein-labeled fragments. Both assay formats use an excitation wavelength of 480-495 nm and an emission wavelength of 515-525 nm.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.